Rhinoplasty and Other Nasal Procedures (Kansas)
Clinical coverage criteria for rhinoplasty and other nasal procedures (including nasal valve repair, rhinophyma excision, nasal polypectomy) applying to UnitedHealthcare community plan members in Kansas.
Medical records documentation may be required to assess whether the member meets the clinical criteria for coverage.
Removed CPT code 30999 from the applicable codes list.
Updated definition of 'External Nasal Valve'.
Updated Description of Services, Clinical Evidence, and References sections to reflect the most current information.
Coverage Criteria for Nasal Procedures
Nasal Valve Procedures/Repair
Covered when ALL of the following are met
Rhinophyma Excision
Covered when ALL of the following are met
Choice of surgical technique should be documented and justified by rhinophyma severity; outcomes and recurrence vary by method.
Nasal Polypectomy
Covered when criteria per referenced InterQual CP are met
See InterQual clinical criteria linked in policy
Rhinoplasty (Adults)
Covered when criteria per referenced InterQual CP are met
See InterQual clinical criteria linked in policy
Rhinoplasty for Congenital Anomalies (Under 18)
Covered when ALL of the following are met
Procedure is limited to congenital-anomaly indications as documented in the record
Rhinoplasty - Primary (Under 18)
Covered when ALL of the following are met
Document prior conservative therapy and photos
Rhinoplasty - Revision (Under 18)
Covered when ALL of the following are met
Documentation should demonstrate prior primary surgery and persistent functional impairment
Rhinoplasty - Tip (Under 18)
Covered when ALL of the following are met
Documentation of photos and conservative therapy required
Medically necessary surgical interventions for nasal valve dysfunction
Covered when ALL of the following are met
AAO-HNS supports surgical repair for appropriately selected patients; evidence base is limited and techniques should be tailored to anatomic cause
Rhinophyma excision
Covered when ALL of the following are met
Retrospective series report high patient satisfaction with combined approaches; document rationale and expected outcomes
Rhinoplasty (functional/reconstructive)
Covered when ALL of the following are met
Systematic reviews report NOSE and VAS improvements though heterogeneity exists; document expected functional benefit
Absorbable nasal implant (Latera) — coverage criteria
Covered when ALL of the following are met
Randomized and prospective studies show symptomatic improvement up to 12 months; longer-term comparative efficacy vs rhinoplasty is uncertain
Septal swell body reduction — coverage criteria
Covered when ALL of the following are met
Prospective studies show NOSE score improvements; long-term comparative data limited
NSB/NST/NVB reduction — evidence and applicability
Evidence from small randomized and observational studies suggests short-term symptomatic improvement for selected patients with NSB/NST/NVB hypertrophy; long-term benefit is unclear.
Yu et al. RCT (n=51) showed short-term benefit of combined SBVR + turbinoplasty vs turbinoplasty alone
PNN/SPG ablation (TCRF or cryo) — evidence and applicability
Multiple RCTs and prospective single-arm studies report clinically meaningful reduction in rhinitis symptom scores and QOL after PNN ablation, with some studies showing sustained benefit to 2–3 years, but heterogeneity and limited long-term controlled data exist.
RCTs and observational studies report responder rates commonly 71–87% with some durability to 24–36 months; limitations include variable follow-up and uncontrolled medication use
Covered when trial-based selection criteria are met
Coverage when ALL of the following trial-aligned criteria are met
Reflects trial inclusion criteria
Trials typically required prior medical therapy failure
Selection should align with trial methodologies
Reflects trial methodologies and supports assessment of benefit
Nasal valve procedures and repair of nasal vestibular stenosis or alar collapse are covered only for the specific functional reconstructive indications described in this policy. Procedures performed for other indications are not considered reconstructive or medically necessary. Use of absorbable polylactic acid nasal cartilage support implants (for example, Latera) is addressed separately: while some studies report symptomatic improvement, the overall evidence is low quality with limited long-term comparative data; implants should only be considered when documentation demonstrates the procedure is intended to treat functional nasal airway obstruction consistent with the policy coverage criteria rather than for cosmetic purposes.
Descriptions of surgical technique alone (for example, listing grafts, flaps, or suture methods) are frequently insufficient to establish medical necessity. Coverage decisions require documentation linking the chosen technical approach to the patient’s anatomic cause of obstruction and to expected functional benefit, ideally including validated patient-reported outcomes or objective airflow measures as described in the policy and supporting literature.
Bioabsorbable nasal implants should not be used solely for cosmetic alteration or when there is no documented functional nasal airway obstruction. The evidence for implants such as Latera is limited by study quality, short- to intermediate-term follow-up, and frequent adjunctive procedures; therefore implant placement without objective or validated documentation that dynamic lateral wall collapse is the primary cause of obstruction is not supported.
Some interventions lack independent, high-quality supportive evidence. In particular, evolving evidence reviews (Hayes) have found minimal or unclear support for certain cryoablation devices (ClariFix) for chronic rhinitis; heterogeneous, often industry-sponsored studies and limited randomized controlled data mean these interventions may be considered experimental or may not meet coverage when submitted without robust supporting data.
Procedures performed for indications that are not represented in the evidence base, or that lack documentation of baseline severity and prior medical therapy, may be excluded from coverage. The policy requires that submitted procedures align with studied indications and that medical records include sufficient baseline symptom measures and prior-treatment history to determine appropriateness.
FDA classification, clearance, or 510(k) status is provided for informational context only and does not by itself establish medical necessity or guarantee coverage. Coverage determinations are based on the clinical evidence and whether the service meets the policy criteria, not solely on regulatory status.
Specific procedures identified in this policy as unproven or not medically necessary include absorbable polylactic acid nasal cartilage support implants (e.g., Latera) for routine use, nasal septal swell body reduction as a general treatment for nasal obstruction when evidence is insufficient, posterior nasal nerve or sphenopalatine ganglion ablation (e.g., RhinAer, ClariFix) when unsupported by high-quality evidence for the submitted indication, and radiofrequency treatment of nasal valves (e.g., VivAer ARC Stylus) when long-term comparative effectiveness and durability have not been established.
Technical modifications or novel techniques for nasal valve surgery that lack supportive outcome data — for example, reports that describe only surgical steps without validated outcome measurement or adequate follow-up — should be considered experimental. Coverage requires evidence that the technique provides sustained, clinically meaningful improvement in patient-reported or objective measures.
Long-term effectiveness and safety data for absorbable nasal implants are limited. When there is insufficient long-term evidence, uncertain durability, or lack of appropriate patient selection and objective outcome data, these implants may be considered experimental or of uncertain clinical benefit and therefore not meet medical necessity criteria.
Isolated cautery or cryosurgery of nasal septal/turbinate swell body (NST/NSB) has not demonstrated benefit in some controlled studies. Where published trials show no advantage, such isolated techniques may be considered not medically necessary unless used in a context and patient population supported by higher-quality evidence.
Use of devices or techniques that lack adequate comparative evidence of long-term effectiveness — or that are applied outside the indications studied in clinical trials — may not be covered. The policy emphasizes alignment between the planned procedure/device and the indication and patient selection criteria used in the supporting studies.
Coding and Procedure Codes
| 30117 | Excision or destruction (e.g., laser) of intranasal lesion; internal approach. |
| 30120 | Excision or surgical planing of skin of nose for rhinophyma. |
| 30400 | Rhinoplasty, primary; lateral and alar cartilages and/or elevation of nasal tip. |
| 30410 | Rhinoplasty, primary; complete, external parts including bony pyramid, lateral and alar cartilages, and/or elevation of nasal tip. |
| 30420 | Rhinoplasty, primary; including major septal repair. |
| 30430 | Rhinoplasty, secondary; minor revision (small amount of nasal tip work). |
| 30435 | Rhinoplasty, secondary; intermediate revision (bony work with osteotomies). |
| 30450 | Rhinoplasty, secondary; major revision (nasal tip work and osteotomies). |
| 30460 | Rhinoplasty for nasal deformity secondary to congenital cleft lip and/or palate, including columellar lengthening; tip only. |
| 30462 | Rhinoplasty for nasal deformity secondary to congenital cleft lip and/or palate, including columellar lengthening; tip, septum, osteotomies. |
| 30465 | Repair of nasal vestibular stenosis (e.g., spreader grafting, lateral nasal wall reconstruction). |
| 30468 | Repair of nasal valve collapse with subcutaneous/submucosal lateral wall implant(s). |
| 30469 | Repair of nasal valve collapse with low energy, temperature-controlled (i.e., radiofrequency) subcutaneous/submucosal remodeling. |
| 31237 | Nasal/sinus endoscopy, surgical; with biopsy, polypectomy or debridement (separate procedure). |
| 31242 | Nasal/sinus endoscopy, surgical; with destruction by radiofrequency ablation, posterior nasal nerve. |
| 31243 | Nasal/sinus endoscopy, surgical; with destruction by cryoablation, posterior nasal nerve. |
| 64999 | Unlisted procedure, nervous system. |
| L8699 | Prosthetic implant, not otherwise specified. |
| No explicit CPT/HCPCS/ICD-10 codes provided in this excerpt |
| LRC | FDA product code category for ENT instruments (informational, device classification) |
| 30999 | CPT 30999 (formerly listed) — removed from applicable codes |
Prior Authorization, Documentation, and Billing Guidance
Prior Authorization Required
Prior Authorization Required: Prior authorization is required for procedures described in this policy. Submit clinical documentation demonstrating that the member meets indication-specific criteria, including diagnosis, prior therapies, and validated baseline symptom scores where applicable. Claims may be subject to coding review to determine reconstructive versus cosmetic intent.
- Verify payer, state, and contract-specific prior authorization rules before scheduling.
- Anticipate review of operative plan, photos, and pre-procedure validated symptom scores (eg, NOSE, rTNSS, SNOT).
Prior Authorization Information — Required Submission Elements
Prior authorization submissions must include: the specific indication for the requested procedure; objective and subjective severity measures (eg, NOSE score for nasal valve procedures, rTNSS for chronic rhinitis procedures); documentation of duration and severity of symptoms; prior conservative therapy tried and failed; and the proposed surgical or procedural plan (including whether concurrent septal/turbinate procedures are planned).
- Indication-specific documentation: diagnosis, physical exam findings (including dynamic collapse with deep inspiration), modified Cottle maneuver results, and endoscopic or photographic documentation.
- Severity documentation: baseline validated PROs (NOSE, rTNSS, SNOT) with numeric scores and severity class where applicable.
- Prior therapy: dates and duration of medical management (eg, ≥4 weeks of intranasal steroids when applicable) and other conservative treatments attempted.
- Procedural plan: description of target (internal/external nasal valve, PNN region, septal swell body), whether grafting or implant is planned, and whether septoplasty/turbinate surgery is concurrent or previously performed.
Prior Authorization: Baseline Symptom Thresholds and Prior Therapy
Baseline symptom thresholds and prior therapy must be documented to support medical necessity. For nasal valve procedures, include baseline NOSE score and duration of obstructive symptoms. For posterior nasal nerve (PNN) or sphenopalatine ganglion ablation (eg, RhinAer, ClariFix, TCRF), document symptom duration ≥6 months and baseline rTNSS with subscores where study eligibility thresholds apply.
- Chronic rhinitis / PNN procedures: document ≥6 months of symptoms and failure of medical management (including ≥4 weeks intranasal steroids and other nasal medications such as antihistamines or anticholinergics). Minimum baseline rTNSS thresholds used in key trials (eg, rTNSS ≥6, with relevant subscores) should be provided when available.
- Nasal valve procedures/TCRF/VivAer: document baseline NOSE score and severity (many studies enrolled NOSE ≥60 for severe disease; provide the numeric NOSE).
- Absorbable implants/Latera: document baseline NOSE score and prior conservative therapy; note prior septal/turbinate surgery if relevant.
Prior Authorization: Baseline Scores and Prior Therapy
Validated baseline symptom scores must be included in prior authorization documentation. Use the most relevant patient-reported outcome for the procedure: NOSE for nasal valve/functional rhinoplasty, rTNSS for chronic rhinitis/PNN procedures, and SNOT when reported. Include numeric baseline scores, component subscores when applicable, and duration between score collection and planned procedure.
- Provide preoperative NOSE score (and severity class) for nasal valve and rhinoplasty indications.
- Provide preoperative 24-hour rTNSS (total and subscores) for chronic rhinitis / PNN ablation requests; document if thresholds used in trials are met.
- Attach completed validated instrument forms or clinic note documenting scores and date collected.
- Document prior medical therapy and objective testing results that corroborate symptom burden (eg, rhinomanometry, acoustic rhinometry) when available.
Evidence Limitations — Risk of Denial
Evidence limitations: Many published studies are small, single-arm, or of low methodological quality. The predominance of low-level evidence and limited long-term comparative data may affect coverage decisions and could lead to denials if documentation does not demonstrate medical necessity or if alternatives with stronger evidence are appropriate.
- Document rationale for chosen procedure vs alternative established treatments (eg, septoplasty, turbinate reduction, conservative therapy).
- Provide objective documentation and validated PROs to support claimed benefit given evidence limitations.
Evidence Limitations May Trigger Denials
Evidence limitations may trigger denials when claims lack indication-specific documentation, long-term benefit data, or comparative effectiveness versus standard surgical approaches. When evidence is scarce or of low quality (eg, single-arm studies, short follow-up, high loss to follow-up), provide robust patient-level documentation showing clinical need and prior therapy failure to mitigate denial risk.
- If requesting newer or device-based treatments (eg, Latera, VivAer, ClariFix), include justification addressing why standard reconstructive approaches are not appropriate for this patient.
- Attach pertinent literature or guideline statements when supportive for the individual case (eg, AAO-HNS position statements).
Evidence Insufficiency Risk — ClariFix
Specific device/procedure evidence insufficiency: For ClariFix cryotherapy, current evidence reviewers (Hayes) report minimal or unclear support. Requests for ClariFix should include strong patient-level justification, prior therapy failure, validated symptom scores, and safety considerations because evidence insufficiency may lead to noncoverage.
- Document prior conservative management and objective/validated symptom measures (eg, rTNSS) showing moderate-to-severe baseline symptoms.
- If comparing options, provide rationale and any comparative outcome data available for the patient.
Insufficient High-Quality Comparative Evidence May Trigger Denial
Insufficient high-quality comparative evidence may trigger denial for some newer procedures (eg, VivAer TCRF for nasal valve remodeling, absorbable implants) when the request lacks documentation that the member is an appropriate candidate or when standard, better-supported alternatives exist. Provide detailed rationale and preauthorization evidence to address comparative gaps.
- Highlight prior attempts at standard surgical interventions or documented reasons they are contraindicated or unlikely to succeed.
- Provide long-term follow-up plans and how outcomes will be measured post-procedure (eg, scheduled PROs, objective airflow testing).
Recommended Clinical Documentation
Recommended clinical documentation to submit with prior authorization: comprehensive history, physical exam, diagnostic test results, preoperative validated PROs (NOSE, rTNSS, SNOT), photos documenting dynamic or anatomic collapse, modified Cottle maneuver results, medication trial history with durations, and the explicit surgical/procedural plan including concurrent procedures.
- History: symptom onset, duration, prior treatments, response to therapies, impact on function/QOL.
- Physical exam: nasal valve collapse on inspiration, endoscopy findings, septal deviation/turbinate status.
- Objective tests: validated PRO scores with dates, rhinomanometry/acoustic rhinometry if available.
- Imaging/photos: preoperative photographs or endoscopic images showing nasal valve anatomy or collapse.
- Treatment plan: clearly stated operative plan, graft/implant need, and whether septoplasty or turbinate procedures are concurrent or previously performed.
Stepwise Treatment Consideration
Stepwise treatment consideration: Prioritize nonoperative care and address contributing anatomic causes before definitive valve procedures. Consider septal deviation repair, turbinate reduction, or medical management prior to or concurrent with nasal valve–directed interventions when clinically appropriate.
- Document consideration of and response to septal and turbinate therapies.
- If concurrent surgery is planned (eg, septoplasty/turbinate reduction with valve repair), document rationale for combined approach.
Consideration of Alternatives
Consideration of Alternatives: Prior authorization should include documentation that less invasive or standard reconstructive approaches were considered. If an implant or novel procedure is requested, explain why traditional reconstructive grafting or other standard techniques are inappropriate or have been previously tried and failed.
- List alternatives considered (medical therapy, septoplasty, turbinate surgery, autologous cartilage grafting) and outcomes or reasons for unsuitability.
- If device-based therapy is chosen, document discussion of risks, benefits, and alternatives in the medical record.
Step Therapy: Medical Management Required First
Step therapy / Conservative management required first: Document a trial and failure of conservative medical management (eg, intranasal corticosteroids, antihistamines, anticholinergics) of adequate duration (typically ≥4 weeks; for some procedures and indications clinical trials required ≥6 months of symptoms) prior to procedural interventions unless there is clear anatomic abnormality requiring surgery.
- For chronic rhinitis/PNN procedures: document ≥6 months of symptoms and inadequate response to medical management including ≥4 weeks of intranasal steroid use.
- For structural nasal obstruction/rhinoplasty and nasal valve repair: document ≥4 weeks (or as specified by contract) of conservative therapy where applicable and note any urgent/traumatic indications where expedited surgery may be appropriate.
Definitions and Terms
Background and Clinical Context
Background: Mechanical nasal airway obstruction is difficulty breathing through the nose caused by bony or cartilaginous deformity. External and internal nasal valve compromise, rhinophyma, and congenital anomalies can produce functional impairment. Reconstructive interventions are intended to correct anatomic causes of obstruction after conservative medical therapy has failed and when objective or photographic evidence documents the anatomic abnormality and its contribution to symptoms.
Policy Revision History
Added requirement that medical records documentation may be requested to assess whether the member meets clinical criteria and clarified what constitutes adequate documentation (history, exam, diagnostic tests) for coverage reviews; updated definition of 'External Nasal Valve' and revised supporting sections (Description of Services, Clinical Evidence, References).
Removed CPT code 30999 from the list of applicable codes.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.